10 recruiting, 2 not yet recruiting, 2 unknown. 11 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 9, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 7 | Recruiting 4, Unknown 2, Not yet recruiting 1 |
Follow SHR-A2102: new trials by email Literature Review of SHR-A2102 trials Research Report on SHR-A2102
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib Study of HS-10504 Combined Therapy in NSCLC HS-10504, SHR-A2009, HS-20122 - Lung Cancer | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 400 | 2026-03-30 | 2026-02-17 |
| A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer SHR-A2102, Adebrelimab, Paclitaxel - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 300 | 2025-11-24 | 2025-12-01 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer SHR-A2102, Adebrelimab, Cetuximab - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 210 | 2025-07-11 | 2026-07-20 |
| Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer SHR-A2102, Adebrelimab - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 48 | 2025-06-30 | 2025-06-27 |
| A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors SHR-A2102, Bevacizumab Injection, Adebelimab Injection - Advanced Solid Tumors | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 400 | 2025-03-28 | 2025-04-22 |
| A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma SHR-A2102, Adebrelimab injection, SHR-8068 injection - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 90 | 2024-11-04 | 2024-11-18 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer SHR-A2102, Adebelimab (SHR-1316), SHR-8068 - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 124 | 2024-09-27 | 2024-11-12 |
| Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer SHR-A1811, SHR-A1921, Adebrelimab - Advanced Breast Cancer | Phase 2 | Recruiting | Beijing GoBroad Hospital | 113 | 2024-08-05 | 2026-07-14 |
| A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors SHR-A2102, SHR-A2102 ; Adebrelimab injection, SHR-A2102 + Disitamab Vedotin For Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 80 | 2024-05-27 | 2026-08-24 |
| Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors SHR-A2102 - Advanced Solid Tumors | Phase 1 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 395 | 2023-04-06 | 2025-07-22 |
| A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. SHR-A2102 - Advanced Or Metastatic Solid Tumor Malignancies | Phase 1 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 252 | 2023-03-03 | 2023-03-28 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| Reverse Triple Negative Immune Resistant Breast Cancer Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate - Triple-negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 90 | 2022-06-30 | 2026-10-23 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Lung Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Shanghai Hengrui Pharmaceutical Co., Ltd. (7) · Fudan University (4) · Beijing GoBroad Hospital (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
China (13)
Hongxia Wang, Chief physician (1) · Wei Zhao (1) · Xichun Hu, Chief physician (1) · Zhimin Shao, M.D. (1) · Zhimin Shao, Professor (1)